Cambridge id 5513753

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Cambridge id 5513753
• 英文别名: 4-(3-methylsulfanylpropyl)morpholine
• 化学式: C₈H₁₇NOS
• 分子量: 175.29
• InChiKey: ODWGKWSTUATCOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Cyclosporin Analogs
  申请人：Garst Michael E.

  公开号：US20120135939A1

  公开（公告）日：2012-05-31

  Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.

  本文披露了环孢素的新型类似物，包含它们的药物组合物，以及它们在治疗干眼症和其他疾病中的使用方法。
• TYK2 inhibitors and uses thereof
  申请人：Nimbus Lakshmi, Inc.

  公开号：US10577373B2

  公开（公告）日：2020-03-03

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了用于抑制 TYK2 和治疗 TYK2 介导的疾病的化合物、其组合物和使用方法。
• Blocking toll-like receptor 9 signaling with small molecule antagonist
  申请人：Council of Scientific & Industrial Research

  公开号：US10662177B2

  公开（公告）日：2020-05-26

  The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.

  本发明涉及小分子 4-(哌嗪-1-基)喹唑啉-2-氨基化合物，其式(I)有助于抑制某些类毒素受体（TLRs），特别是 TLR9 的信号传导。类毒素受体（TLRs）是进化保守的模式识别受体大家族的成员，是宿主免疫反应识别自我和非自我的关键第一道防线。TLR9的异常激活与不同自身免疫性疾病中的自身反应性炎症有关。本发明描述的式(I)化合物、组合物和方法可用于多种临床应用，包括作为药物制剂和方法用于治疗因TLR9活化而导致的不需要的免疫活动。
• Benzimidazole derivatives: preparation and pharmaceutical applications
  申请人：MEI Pharma, Inc.

  公开号：US10736881B2

  公开（公告）日：2020-08-11

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).

  本发明涉及作为组蛋白去乙酰化酶抑制剂的羟酰胺化合物。更具体地说，本发明涉及含苯并咪唑的化合物及其制备方法。这些化合物可用作治疗增殖性疾病以及涉及组蛋白去乙酰化酶（HDAC）失调或与之有关的其他疾病的药物。
• Human helicase DDX3 inhibitors as therapeutic agents
  申请人：AZIENDA OSPEDALIERA UNIVERSITARIA SENESE

  公开号：US10941121B2

  公开（公告）日：2021-03-09

  The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

  本发明是指具有式 I 和 II 的 RNA 螺旋酶 DDX3 抑制活性的化合物及其治疗用途，特别是用于治疗病毒性疾病。